The third derivative recently approved in 2017 by the FDA14 and the EMA15 is midostaurin (CGP41251, PKC412, Rydapt®) (Novartis) (Figure 3), described mainly as the first fms-like tyrosine kinase 3 (FLT3) inhibitor for newly diagnosed acute myeloid leukemia (AML) and for advanced systemic mastocytosis (SM)16,.17 The gene discussed is FLT3; the disease is systemic mastocytosis.